US2011082085A1PendingUtilityA1

Peptides derived from the c2 domain of epsilon pkc and methods of use, thereof

37
Assignee: UNIV LELAND STANFORD JUNIORPriority: Oct 2, 2006Filed: Dec 3, 2010Published: Apr 7, 2011
Est. expiryOct 2, 2026(~0.1 yrs left)· nominal 20-yr term from priority
Inventors:Daria Mochly-RosenRelly Brandman
C12Y 207/11013A61P 9/10C12N 9/1205A61K 38/45A61P 9/00A61P 43/00
37
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Peptides derived from the C2 regions of εPKC and methods of use, thereof, are described. These peptides modulate the activity of εPKC in an animal model of acute ischemic heart disease.

Claims

exact text as granted — not AI-modified
1 . A method for modulating ischemic cardiac damage in a mammalian subject comprising administering a therapeutically effective amount of a peptide comprising a contiguous amino acid sequence derived from the C2 domain of εPKC. 
     
     
         2 . The method of  claim 1 , wherein the peptide does not include an amino acid sequence corresponding to amino acid residues 85-92 of the C2 domain of εPKC. 
     
     
         3 . The method of  claim 1 , wherein the εPKC peptide is not ψεRACK (SEQ ID NO:18). 
     
     
         4 . The method of  claim 1 , wherein the εPKC peptide comprises a contiguous amino acid sequence corresponding to amino acid residues 28-35, 49-60, and 74-79, of εPKC. 
     
     
         5 . The method of  claim 1 , wherein the εPKC peptide comprises a contiguous amino acid sequence corresponding to a sequence selected from the group consisting of SEQ ID NO:9, SEQ ID NO:12, SEQ ID NO:1.3, and SEQ ID NO:16. 
     
     
         6 . The method of  claim 4 , wherein the εPKC peptide comprises a contiguous amino acid sequence corresponding to amino acid residues 28-35, 49-53, and 74-79, of εPKC. 
     
     
         7 . The method of  claim 5 , wherein the εPKC peptide comprises a contiguous amino acid sequence corresponding to a sequence selected from the group consisting of SEQ ID NO: 9, SEQ ID NO: 12, and SEQ ID NO: 16. 
     
     
         8 . The method of  claim 2 , wherein the εPKC peptide corresponds to the beta-sandwich region of the C2 domain of εPKC. 
     
     
         9 . The method of  claim 1 , wherein the peptide is conjugated to a carrier peptide. 
     
     
         10 . The method of  claim 9 , wherein the carrier peptide comprises SEQ ID NO:31 or SEQ ID NO:32. 
     
     
         11 . The method of  claim 9 , wherein the peptide is cross-linked to the carrier peptide by an N-terminal Cys-Cys bond. 
     
     
         12 . The method of  claim 1 , wherein the mammalian subject is a heart transplant patient.

Join the waitlist — get patent alerts

Track US2011082085A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.